Shanghai Junshi Biosciences Co., Ltd. (SHA:688180)
31.54
-0.16 (-0.50%)
Apr 3, 2025, 2:45 PM CST
SHA:688180 Revenue
In the year 2024, Shanghai Junshi Biosciences had annual revenue of 1.95B CNY with 29.67% growth. Shanghai Junshi Biosciences had revenue of 677.12M in the quarter ending December 31, 2024, with 31.20% growth.
Revenue
1.95B
Revenue Growth
+29.67%
P/S Ratio
n/a
Revenue / Employee
755.75K
Employees
2,568
Market Cap
27.35B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.95B | 445.77M | 29.67% |
Dec 31, 2023 | 1.50B | 49.06M | 3.38% |
Dec 31, 2022 | 1.45B | -2.57B | -63.89% |
Dec 31, 2021 | 4.02B | 2.43B | 152.36% |
Dec 31, 2020 | 1.59B | 819.81M | 105.77% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Jiangsu Hengrui Medicine | 27.98B |
Shenzhen Mindray Bio-Medical Electronics | 37.11B |
WuXi AppTec | 37.92B |
Aier Eye Hospital Group | 20.62B |
Zhangzhou Pientzehuang Pharmaceutical., | 10.91B |
Shanghai United Imaging Healthcare | 10.30B |
Yunnan Baiyao Group Co.,Ltd | 40.03B |
Sichuan Biokin Pharmaceutical | 5.82B |